Safer, Cheaper and Just as Good: Making Sterile, 7-Day Platelets a Reality James P. AuBuchon, MD E. Elizabeth French Professor and Chair of Pathology Dartmouth-Hitchcock.

Slides:



Advertisements
Similar presentations
Part 2 Terry Kotrla, MS, MT(ASCP)BB
Advertisements

Experience of the Irish Blood Transfusion Service William G. Murphy MD
Update on the AABB Standards and platelet bacterial contamination TAC: MVRBC 2011.
IDENTIFIKASI BAKTERI OLEHSUDRAJAT FMIPA UNMUL 2009.
URINARY TRACT INFECTION
●BIOCHEMOCAL UNKNOWN ●OXIDATION/ FERMENTATION ●CATALASE ●oXIDASE
Bacterial Contamination and Screening of Platelet Concentrates
Bacterial Testing of Platelet Components: 2008 Update William B. Lockwood, PhD, MD Clinical Professor Department of Pathology & Laboratory Medicine University.
Gambro/Fenwal PASSPORT Post Marketing Study – 7 Day Platelets Blood Products Advisory Committee Rockville, MD May 1, 2008 Larry J. Dumont, MBA, PhD Dartmouth-Hitchcock.
A summary review provided by the American Red Cross Blood Services Regions serving the North Atlantic Area July, 2003 Bacterial Contamination in Blood.
Single-Donor Platelets: Arguments for Preferential Use Paul M. Ness, MD Transfusion Medicine Division Johns Hopkins Medical Institutions.
Quality Control And Pathogen Inactivation of Platelets
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Evaluation of Rapid Screening Methods for Emergency Blood Collections CPT Robert.
Comparison of the Diagnostic Value of the Standard Tube Agglutination Test and the ELISA IgG and IgM in Patients with Brucellosis Presented by Dr. Md.
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download,
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
Gram Stains of Bacteria
Draft Guidance: Collection of Platelets by Automated Methods Comments to the Docket and Questions for the Committee Alan E. Williams, Ph.D. Director,
Questions for Microbiology (practical)
1 Quality Control Procedures During Autotransfusion AmSECT New Advances in Blood Management Meeting Seattle, Washington September 8, 2011John Rivera.
Microbiological Considerations in Diagnosing S. aureus Bacteremia Patrick R. Murray, Ph.D. NIH Clinical Center Chief, Microbiology Laboratories.
C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.
Microbial Testing of Cell Therapy Products Summary of NIH Clinical Center Studies Elizabeth Read MD Chief, Cell Processing Section Department of Transfusion.
GURU BRAHMA GURU VISHNU GURU DEVO MAHESWARAHA GURU SHATHSHATH
Korde N et al. Proc ASH 2014;Abstract 2105.
Identification of Pathogenic Bacteria by Laboratory Methods M. Kent Froberg, MD.
Clinical Microbiology ( MLCM- 201) Prof. Dr. Ebtisam.F. El Ghazzawi. Medical Research Institute (MRI) Alexandria University.
Dr Anand Deshpande P D Hinduja National Hospital & MRC Mumbai.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Red Cell In Vivo Recovery and Survival Studies Richard J. Davey, MD The Methodist Hospital, Houston TX Blood Products Advisory Committee May 1, 2008.
Surveillance of Antibiotic Resistance at Sihanouk Hospital Center of HOPE ( ) Phe Thong, MD; Erika Vlieghe, MD PhD; Lim Kruy, MD; Veng Chhunheng,
1 Verax Biomedical Platelet PGD ® Test. 2 Verax Biomedical Platelet PGD ® Test Results in approximately 30 minutes Designed for use with LR or non-LR:
Vesicle-Mediated Transfer of Antibiotic Resistance Between Klebsiella pneumoniae and Serratia marcescens Ondraya Espenshade Department of Biological Sciences,
Beyond the Pale: the Ethics of Gifts Professor Andrew Zolani Cakana (FIBMS; MB ChB; CTM; M Med Sc.; FRCPath).
Bacterial Screening of Platelet Concentrates by Real-Time PCR Theo Cuypers 1 also on behalf of, H.W. Reesink 1,3 I.G.H. Rood 1,2 T. Mohammadi¹, ²P.H.M.
Apheresis Blood Components
Can Urine Clarity Exclude the Diagnosis of Urinary Tract Infection? Date: 2002/6/28 黃錦鳳 / 黃玉純.
April The American Red Cross experience with TRALI Richard J Benjamin MD PhD Chief Medical Officer American Red Cross, Biomedical Headquarters Washington.
Exp 1: Culture Transfer Techniques , with organisms
Module 1: The Journey of Blood: Donation to Distribution Transfusion Training Workshop KKM 2012.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland.
QUALITY ASSURANCE & QUALITY CONTROL OF BLOOD COMPONENTS
1 BacTx ™ Kit for Detection of Bacterial Contamination of Platelets Andrew E. Levin, Ph.D. Immunetics, Inc. Blood Products Advisory Council Meeting March.
Antibacterial Effect of Chitosan Flakes: Application to Water Treatment Yves ANDRES, Laurence GIRAUD and Pierre Le CLOIREC Ecole des Mines de Nantes,
FDA’s Criteria for Evaluation of Red Blood Cell Products Ping He, M.D. Medical Officer Blood Products Advisory Committee 91st Meeting, May 1, 2008 Rockville.
FDA Update: Particulate Matter Task Force Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting June 19, 2003.
ANALYTICAL PROCESS CONTROL
Urinary Tract Infection Department of Microbiology
Bacterial identification
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
Evaluation of Proposed FDA Criteria for Evaluation of Radiolabeled Red Cell Recovery Trials Larry J. Dumont, MBA, PhD James P. AuBuchon, MD for the Biomedical.
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
Michael R. Jacobs, MD, PhD Roslyn Yomtovian, MD
Automated Blood Cultures 韩向阳 Xiang-Yang Han, MD, PhD Department of Laboratory Medicine The University of Texas M. D. Anderson Cancer Center.
lecture 10 blood bank Compatibility Testing
SVTM 17.Sept.2005 M. Senn Hemovigilance : Risks of the Blood Transfusion Process Marianne Senn, ART (CSMLS) Head of Hemovigilance Swissmedic / Swiss Agency.
Laboratory Diagnosis Chapter 8. APPROACH TO LABORATORY DIAGNOSIS ● The laboratory diagnosis of infectious diseases involves two main approaches, the bacteriologic.
Ann Intern Med. 2012;157(1): doi: / Figure Legend:
Compatibility Testing
WITH MCS+ AND TRIMA SEPARATORS.
Critical Appraisal of the European CAS Trials
Benefits of apheresis collection
Pathogen Reduced Platelets: The Next Big Thing in Transfusion Safety
Detection of bacteria in blood products
Neonatal sepsis in Kilifi
Dinty J. Musk, David A. Banko, Paul J. Hergenrother 
Presentation transcript:

Safer, Cheaper and Just as Good: Making Sterile, 7-Day Platelets a Reality James P. AuBuchon, MD E. Elizabeth French Professor and Chair of Pathology Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire

Safer, Cheaper and Just as Good: Making Sterile, 7-Day Platelets a Reality 1: Why we are interested in this 2: Whether it is feasible

Comparison of Residual Risks HIV HBV HCV :100 1:1000 1: : : Transmission risk, per unit Updated from: Goodnough LT e t al. NEJM 1999;341:126-7

Comparison of Residual Risks BacterialContamination(platelets) SepticFatalities(platelets) HIV HBV HCV :100 1:1000 1: : : Transmission risk, per unit Updated from: Goodnough LT e t al. NEJM 1999;341:126-7

Red Blood Cells Platelets 200 mL red cells 30 mL plasma 110 mL additive solution 4 x platelets 300 mL plasma What Are You Transfusing?

Red Blood Cells Platelets 200 mL red cells 30 mL plasma 110 mL additive solution 10 9 Yersinia per mL + endotoxin 4 x platelets 300 mL plasma 10 8 Staph per mL What Are You Transfusing?

The Problem with Platelets… Bacterial contamination is - frequent - initially at very low concentration - very difficult to detect - in unit - in patient

Unit TransfusedRisk per Million Units Confirmed Report ofFatality Confirmed Report ofFatality Bacterial Contamination Red Blood Cells Plateletpheresis units327.1 TOTAL, all units Perez P et al. Transfusion 1999;39:2S. Bacterial Contamination Risks

Unit TransfusedRisk per Million Units Confirmed Report ofFatality Confirmed Report ofFatality Bacterial Contamination Red Blood Cells Plateletpheresis units327.1 TOTAL, all units Perez P et al. Transfusion 1999;39:2S. Bacterial Contamination Risks 1/140,000

Clinical cases of post-transfusion sepsis per year Fatalities per year BaCon Report, 1999 AABB Annual Meeting. Kuehnert et al. Transfusion 2001;41: U.S. Bacterial Contamination Estimates Based on BaCon Preliminary Data

Platelet contamination rate: US 670/million units(Transfusion 1999;39:36S) Germany1300 (Transfusion 1999;39:34S) Spain 320 (Transfusion 1999;39:75S) Frequency of Contamination Other Reports

Frequency of Contamination Other Reports Ness PM et al. Transfusion 2001;41: Recalculation: LJ Dumont. Plt Conc SDP Plt Conc SDP Post-transfusion sepsis 402/million75/million Fatalities 62/million14/million Based on Johns Hopkins’ Data

Detecting Bacteria in Platelets: Inspection Changes Associated with Contamination ClotsDiscoloration Gas bubbles

Detecting Bacteria in Platelets: Microscopic Review Sensitivity: Gram stain /mL Acridine orange /mL Barrett et al. Transfusion 1993;33:228-4.

Detecting Bacteria in Platelets: Microscopic Review Sensitivity: Gram stain /mL Acridine orange /mL But: Significant false positive rate Barrett et al. Transfusion 1993;33:

Detecting Bacteria in Platelets: Biochemical Changes GLUCOSE ACID + CO 2 Decreased glucose Decreased pH Decreased/absent swirling Direct detection

GLUCOSE ACID + CO 2 Decreased glucose Decreased pH Decreased/absent swirling Automated testing Automated testing Biochemical strips Biochemical strips Direct detection Sensitive labels Sensitive labels Automated culture Automated culture Detecting Bacteria in Platelets: Biochemical Changes

CO 2 -sensitive labels on platelet bags: No change withStaph. epi Staph. aureus Ps. aeruginosa Bacillus cereus Change only withEnt. aerogenes at > 10 6 CFU/mL at > 10 6 CFU/mL sensitivity = 20% sensitivity = 20% Specificity problem: Platelets produce CO 2 also. Hogman CF, Gong J. Vox Sang 1994;67: Detecting Bacteria in Platelets: Biochemical Changes

Glucose, % Day 0 Storage Time, d data from Burstain JM et al. Transfusion 1997;37: Detecting Bacteria in Platelets: Biochemical Changes

Glucose, % Day 0 Storage Time, d after Burstain JM et al. Transfusion 1997;37: SD Detecting Bacteria in Platelets: Biochemical Changes

Swirling Low pH Metabolic disturbance No alignment with flow Alignment with flow

Detecting Bacteria in Platelets: Biochemical Changes Swirling to detect contamination SensitivitySpecificity SensitivitySpecificity S. epi. 25% (Day 5) 75% S. aureus100% (Day 2-3) 100% Salmonella 75% (Day 3-5) 100% Leach MF et al. Vox Sang 1998;74(suppl 1):1180.

Detecting Bacteria in Platelets: Biochemical Changes Wagner SJ, Robinette D. Transfusion 1996;36: False positive rates (sterile units) Glucose:5% pH:4% Swirling:5% based on ±2 SD reference intervals

Brecher et al. Transfusion 1993;33: Fenwick et al. Lancet 1991;337:496-7 Detecting Bacteria in Platelets: Future Developments PCREIA %O 2 Others….

Traditional Concept BLOOD CENTER Culture: Day 1 Hold until negative HOSPITAL Day 2 or 3 Detecting Bacteria in Platelets: Culturing

Traditional Concept BLOOD CENTER Culture: Day 1 Hold until negative HOSPITAL Day 2 or 3 Detecting Bacteria in Platelets: Culturing - Currently in routine use in blood centers in Belgium and the Netherlands - Potential difficulties with recall, outdating.

New Concept: Hospital-Based Verification of Sterility Detecting Bacteria in Platelets: Culturing

(5 mL via SCD) New Concept: Hospital-Based Verification of Sterility Detecting Bacteria in Platelets: Culturing BacT Alert ENTRY INTO INVENTORY DAY 2: CULTURE TRANSFUSION ORDER: RELEASE UNIT

Detecting Bacteria in Platelets: Culturing Organisms Involved in Blood Unit Contamination Gram-positive (60%)Gram-negative (40%) Staph. epi* (8) E. coli (5) Staph. aureus (4) Serratia marcescens* (3) Staph. agalactiae (2) Serratia liquifaciens* (2) Grp G Strep. (1) Enterobacter aerogenes (1) Staph. lugdensis (1) Enterobacter cloacae (1) Staph. saprophyticus (1) P. rettgeri (1) Bacillus cereus (1) Y. enterocolitica (1) E. faecalis (1) Strep. pneumoniae (1) *includes isolates from RBCs Kuehnert et al. Transfusion 2001;41:

Leach MF et al. Vox Sang 1998;74(suppl 1):1180. Bacterial Growth Kinetics in Platelets Storage time, d Bacterial concentration/mL Inoculation: 1 CFU/mL Detecting Bacteria in Platelets: Culturing

Brecher M et al. Transfusion 2001;41: Detecting Bacteria in Platelets: Culturing Time to Detection in an Automated Culturing System Inoculum: 4 mL

New Concept: Hospital-Based Verification of Sterility Detecting Bacteria in Platelets: Culturing BacT Alert ENTRY INTO INVENTORY DAY 2: CULTURE TRANSFUSION ORDER: RELEASE UNIT POSITIVE AUTOMATED CULTURE Interdiction of release

New Concept: Hospital-Based Verification of Sterility Detecting Bacteria in Platelets: Culturing BacT Alert ENTRY INTO INVENTORY DAY 2: CULTURE TRANSFUSION ORDER: RELEASE UNIT POSITIVE AUTOMATED CULTURE Interdiction of release Providing: Assurance of sterility Storage to 7 days Storage after pooling Reduced cost for leukoreduction

Practical Application of Culturing in a Transfusion Service Laboratory Experience in first 2 years: 2,569 units cultured (5 mL into aerobic bottle, BacT/Alert automated system) 16 initial positives (0.6%) 11 not confirmed on repeat culture 5 not able to be recultured (1: positive after transfusion) (1: positive after transfusion) May, April, 2001

Practical Application of Culturing in a Transfusion Service Laboratory Recent experience: Split double SDP unit received (external source) Day 2: Culture Day 3 AM: Split A’s culture growth (recultured) Day 3 PM: Split B’s culture growth Same Staph. epi. in each unit. July, 2001

Practical Application of Culturing in a Transfusion Service Laboratory Costs: Material costs: $11.05/plateletpheresis unit Tech time: 7 minutes Workup of positives: $ Cooper L et al. Transfusion 1999;39:119-20S.

Practical Application of Culturing in a Transfusion Service Laboratory Cost (for 100 units): Material costs: $1105 Tech time: 700 minutes $467 Workup of positive: $75 $1647 Units not outdated: $500$7500

Practical Application of Culturing in a Transfusion Service Laboratory Potential payback: Outdate extension Units expiringUnits requested on next day on next day 2.4± ± ± ±2.4 (1-5) (2-9) (1-5) (2-9) In all cases, more units were requested than expired.

BUT: Do 7 day old platelets survive and function? Leach MF, AuBuchon JP. Transfusion 1993;33: Storage Time (d)

A Controlled Trial of 5 vs. 7 Day Platelet Storage Dartmouth-Hitchcock Medical CenterAmerican Red Cross, Norfolk James P. AuBuchon, MDJohn B. Nobiletti, MD Louise Herschel, BS, MLT(ASCP), CCRC Deanna A. McNeil,MLT(ASCP) Jill Roger, MT(ASCP), CCRCSherrie L. Sawyer, MS Adrienne Johnson, BS Gambro Pamela H. Whitley, MT(ASCP)SBB Larry Dumont Art Hamstra Tania VandenBroeke, MT(ASCP) Trima™ Spectra™ LRS Turbo LR SDP Day 1 Day 5 Day 7 Flatbed agitation, 22-24°C Biochemical assays Functional assays 51 Cr/ 111 In recovery and survival and survival XXXXXXXX

A Controlled Trial of 5 vs. 7 Day Platelet Storage Unit contents Platelets:4.1±1.1x10 11 Leukocytes:5.0x10 4 (median) Volume:269±68 mL Mean ± 1 SD

A Controlled Trial of 5 vs. 7 Day Platelet Storage pCO 2 pO 2 pH (22°C) Storage Time (d) mm Hg Storage Time (d) * *

A Controlled Trial of 5 vs. 7 Day Platelet Storage Gluc, Lact, Rate Mean± 1 SEM * * Rates: No difference Storage Time (d) 12

A Controlled Trial of 5 vs. 7 Day Platelet Storage Storage Time (d) % * * * Mean± 1 SEM

A Controlled Trial of 5 vs. 7 Day Platelet Storage Day 5Day 7 * * Mean± 1 SEM

A Controlled Trial of 5 vs. 7 Day Platelet Storage 5 Days7 Days Recovery This study63±11%54±14% Archer et al., ±17%46±8% Survival This study6.7±1.6d5.6±1.9d Archer et al., ±1.5d2.7±0.5d Archer et al. Vox Sang 1982; 43: Mean ± 1SD

A Controlled Trial of 5 vs. 7 Day Platelet Storage 5 Days7 Days Recovery This study63±11%54±14% Archer et al.59±17%46±8% Survival This study6.7±1.6d5.6±1.9d Archer et al.3.4±1.5d2.7±0.5d Archer et al. Vox Sang 1982; 43: Mean ± 1SD THIS STUDY: Better results than accepted previously 6

A Controlled Trial of 5 vs. 7 Day Platelet Storage 5 Days7 Days Recovery This study63±11%54±14% Archer et al., ±17%46±8% Survival This study6.7±1.6d5.6±1.9d Archer et al., ±1.5d2.7±0.5d Archer et al. Vox Sang 1982; 43: Mean ± 1SD THIS STUDY: Better results than accepted previously THIS STUDY: Less reduction D5 D7 14 vs. 22% 18 vs. 21% 6

Practical Application of Culturing in a Transfusion Service Laboratory Day 2 Day 5 Day 7 Flatbed agitation, 22-24°C Day 6 LR SDP OUTDATE Day 8 Transfuse if no other unitsavailable pH and swirling checks DetermineCCI

Practical Application of Culturing in a Transfusion Service Laboratory Day 8 analysis (n = 91) Swirling:96% pH:6.86±0.245 > 6.2 in 97% Max = 7.26 All units collected on Spectra™ LRS Turbo

Practical Application of Culturing in a Transfusion Service Laboratory Transfusions beyond Day 5 (n=40) All with expected clinical results Stable patients with min CCI: 21 All units collected on Spectra™ LRS Turbo

CCI at Day 6-7: 14,400±8,800 Median: 12,191 (n=21) Clinical Effect of Transfusing Platelets Beyond Day 5

Cumulative Proportion (%) 90% > 7,500 (All but 1: > 5,000)

What if 7d platelets aren’t quite as good? PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost CULTURE + 7d NOCULTURE

What if 7d platelets aren’t quite as good? PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost Per-unit HIV risk: 1/1,000,000 Risks expressed per million NOCULTURE CULTURE + 7d

What if 7d platelets aren’t quite as good? PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost Per-unit HIV risk: 1/1,000,000 Septic mortality: 1/140,000 Risks expressed per million NOCULTURE CULTURE + 7d

What if 7d platelets aren’t quite as good? PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost $5,000 0$5, $5,000 0$5, $5,500$220$5, $5,500$220$5,720 Per-unit costs: SDP:$500 Culture:$20 Risks expressed per million NOCULTURE CULTURE + 7d Per-unit HIV risk: 1/1,000,000 Septic mortality: 1/140,000

What if 7d platelets aren’t quite as good? PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost $5,000 0$5, $5,000 0$5, $5,500$220$5, $5,500$220$5,720 Per-unit costs: SDP:$500 Culture:$20 Risks expressed per million $65/unit NOCULTURE CULTURE + 7d Per-unit HIV risk: 1/1,000,000 Septic mortality: 1/140,000

PltHIV SepticTotalUnits’CulturingTotal Direct PltHIV SepticTotalUnits’CulturingTotal Direct TrxnRiskMortality RiskCost Cost Cost $5,000 0$5, $5,000 0$5, $5,500$220$5, $5,500$220$5,720 What if 7d platelets aren’t quite as good? Per-unit costs: SDP:$500 Culture:$20 Risks expressed per million $65/unit OUTDATE REDUCTIONS NOCULTURE CULTURE + 7d Per-unit HIV risk: 1/1,000,000 Septic mortality: 1/140,000

Other applications of culturing + 7d dating -- Prestorage pooling of platelet concentrates - simplicity for transfusion service - prestorage leukoreduction - reduction in filtration cost - sterility assessment in highest-risk component - reduced outdating

Therefore - Platelet storage for 7d is feasible - Adequate maintenance of function - Expected recovery and survival - Adequate clinical efficacy indistinguishable from shorter storage - Bacterial culturing to reduce septic risk - Reduction in overall risk - No increase in cost -- therefore practical Safer, Cheaper and Just as Good Making Sterile, 7-Day Platelets a Reality